Table 3.
Model 1* | Model 2** | Model 3*** | |||||||
n | Events | HR (95% C.I.) | p-value | HR (95% C.I.) | p-value | HR (95% C.I.) | p-value | p for trend | |
Time to first recurrence | |||||||||
250–850 mL | 116 | 45 | ref | ref | ref | 0.65 | |||
850–1200 mL | 124 | 48 | 1.08 (0.72–1.63) | 0.71 | 1.04 (0.69–1.57) | 0.86 | 1.07 (0.71–1.61) | 0.76 | |
>1200 mL | 139 | 46 | 0.81 (0.54–1.21) | 0.31 | 0.80 (0.53–1.20) | 0.27 | 0.91 (0.60–1.37) | 0.65 | |
Time to multiple recurrences | |||||||||
250–850 mL | 116 | 67 | ref | ref | ref | 0.53 | |||
850–1200 mL | 124 | 71 | 1.07 (0.91–1.25) | 0.41 | 1.06 (0.91–1.24) | 0.43 | 1.08 (0.91–1.27) | 0.38 | |
>1200 mL | 139 | 68 | 1.05 (0.87–1.26) | 0.63 | 1.04 (0.86–1.26) | 0.67 | 1.06 (0.89–1.26) | 0.54 |
*Model 1 is unadjusted, **Model 2 is adjusted for age, sex, and smoking status, ***Model 3 is adjusted for age, sex, smoking status, tumour stage, grade, size and multiplicity. In the time to multiple recurrences analyses, Model 2 and Model 3 were additionally adjusted for the variable re-resection of a bladder tumour (second transurethral resection).